Selz Capital’s Gilead Sciences GILD Stock Holding History

Selz Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-70,000	Closed	-$5.01M	–	72
2017 Q4	$5.01M	Hold	70,000	–	–	0.74%	36
2017 Q3	$5.67M	Hold	70,000	–	–	1.14%	25
2017 Q2	$4.96M	Hold	70,000	–	–	1.4%	17
2017 Q1	$4.75M	Sell	70,000 -80,000	-53%	-$5.63M	1.24%	21
2016 Q4	$10.7M	Sell	150,000 -40,000	-21%	-$2.97M	2.76%	10
2016 Q3	$15M	Hold	190,000	–	–	3.5%	6
2016 Q2	$15.8M	Buy	190,000 +40,000	+27%	+$3.55M	4.51%	5
2016 Q1	$13.8M	Buy	150,000 +20,000	+15%	+$1.8M	4.19%	6
2015 Q4	$13.2M	Hold	130,000	–	–	3.8%	8
2015 Q3	$12.8M	Sell	130,000 -50,000	-28%	-$5.55M	3.52%	5
2015 Q2	$21.1M	Sell	180,000 -120,000	-40%	-$13.1M	3.8%	7
2015 Q1	$29.4M	Buy	300,000 +100,000	+50%	+$10.2M	5.07%	6
2014 Q4	$18.9M	Hold	200,000	–	–	5.91%	4
2014 Q3	$21.3M	Hold	200,000	–	–	6.92%	4
2014 Q2	$16.6M	Buy	200,000 +90,000	+82%	+$7.01M	4.39%	5
2014 Q1	$7.79M	Buy	+110,000	New	+$8.63M	1.96%	19

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Selz Capital's GILD Position: Q1 2018 in Review

Selz Capital sold out of Gilead Sciences (GILD) in Q1 2018, closing a stake of 70,000 shares — an estimated $5.01M sold.

Selz Capital first reported a position in GILD in Q1 2014 and held it in 16 quarters. The position peaked at $29.4M in Q1 2015. 1,563 funds tracked by Wall St. Rank hold GILD as of Q1 2018.

Selz Capital reported no remaining Gilead Sciences position as of Q1 2018 after selling out during the quarter.
Selz Capital sold 70,000 Gilead Sciences shares in Q1 2018, an estimated $5.01M.
Selz Capital first reported a position in Gilead Sciences in Q1 2014 and held it in 16 quarters.
Selz Capital's Gilead Sciences position peaked at $29.4M in Q1 2015.
1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2018.

Based on Selz Capital's 13F filing for Q1 2018, filed 13 Apr 2018.